Table 2.
Comparison of clinical and biochemical parameters at baseline and 24 weeks
| Teneligliptin (n = 22) | Sitagliptin (n = 23) | P1 value | P2 value | |||
|---|---|---|---|---|---|---|
| Baseline | 24 weeks | Baseline | 24 weeks | |||
| HbA1c % (NGSP) | 8.1 ± 1.4 | 8.0 ± 1.2 | 8.0 ± 1.7 | 7.9 ± 1.4 | 0.27 | 0.39 |
| Fasting glucose (mg/dL) | 161.5 ± 49.7 | 157.7 ± 31.7 | 150.0 ± 26.3 | 161.7 ± 33.6 | 0.8 | 0.19 |
| C-peptide (ng/mL) | 1.8 ± 0.9 | 2.0 ± 0.6 | 2.5 ± 1.0 | 2.5 ± 1.1 | 0.32 | 0.33 |
| SBP (mmHg) | 133.3 ± 13.4 | 132.4 ± 14.2 | 139.1 ± 22.9 | 131.4 ± 16.8 | 0.79 | 0.06 |
| DBP (mmHg) | 76.1 ± 11.0 | 74.0 ± 10.9 | 79.3 ± 17.0 | 75.4 ± 12.8 | 0.5 | 0.07 |
| LDL-C (mg/dL) | 107.1 ± 21.3 | 105.3 ± 19.4 | 98.2 ± 21.5 | 98.7 ± 21.6 | 0.71 | 0.91 |
| HDL-C (mg/dL) | 53.4 ± 13.2 | 50.7 ± 12.0 | 55.5 ± 16.8 | 50.1 ± 9.1 | 0.12 | 0.06 |
| TG (mg/dL) | 120.3 ± 41.3 | 129.3 ± 60.1 | 156.1 ± 99.9 | 149.0 ± 70.2 | 0.51 | 0.61 |
| eGFR (ml/min−1/1.73 m2) | 43.5 ± 15.8 | 42.8 ± 16.7 | 39.6 ± 15.9 | 39.2 ± 16.2 | 0.36 | 0.77 |
| Urinary albumin (mg/g Cre) | 141.0 (93.5–299.5) | 176.0 (84.5-268.0) | 141.5 (67.0–729.3) | 165.5 (52.8-546.0) | 0.58 | 0.32 |
| Log urinary albumin (mg/g Cre) | 2.3 ± 0.5 | 2.3 ± 0.5 | 2.3 ± 0.6 | 2.3 ± 0.6 | 0.73 | 0.25 |
| Urinary 8-OHdG (ng/mg Cre) | 7.1 ± 4.9 | 5.4 ± 2.9 | 6.4 ± 1.5 | 7.4 ± 2.1 | 0.03* | 0.1 |
| Urinary L-FABP (µg/g Cre) | 25.7 (6.3–118.0) | 14.5 (7.0–64.9) | 48.2 (7.2–91.9) | 55.0 (9.6–110.8) | 0.02* | 0.22 |
| Urinary 8-isoprostane (pg/mgCr) | 199.0 (151.5–424.0) | 297.0 (212.5–440.0) | 258.0 (227.0–429.0) | 353.0 (301.0–578.0) | 0.06 | 0.01* |
Data are mean ± SD or median and interquartile range
SBP systolic blood pressure, DBP diastolic blood pressure, LDL-C low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, TG triglycerides, eGER estimated glomerular filtration rate, 8-OHdG 8-hydroxy-2′-deoxyguanosine, L-FABP liver-type fatty acid binding protein
* P1 value: <0.05, comparison of respective data between baseline and after 24 weeks treatment with teneligliptin
* P2 value: <0.05, comparison of respective data between baseline and after 6 month treatment with sitagliptin